Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy.

Li, Haohao; Zhao, Alison; Li, Menghua; Shi, Lizhi; Han, Qiuju; Hou, Zhaohua

Li, Haohao; Zhao, Alison; Li, Menghua; Shi, Lizhi; Han, Qiuju; Hou, Zhaohua.

Affiliation

Li H; Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Zhao A; Cleveland Clinic Lerner College of Medicine at Case Western Reserve School of Medicine, Cleveland, OH, United States.
Li M; Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Shi L; Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Han Q; Institute of Immunopharmaceutical Sciences, School of Pharmaceutical Sciences, Shandong University, Jinan, Shandong, China.
Hou Z; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Front Immunol ; 13: 1046755, 2022.

Article de En | MEDLINE | ID: mdl-36569893

Sujet(s)
Mots clés

T cell metabolism; immune checkpoint; immune checkpoints inhibitor; metabolic reprogramming; tumor microenvironment

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Lymphocytes T / Tumeurs Limites: Humans Langue: En Journal: Front Immunol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google